Caseware UK (AP4) 2025.0.111 2025.0.111 2025-06-30 1489992 923582 3070 4605 6394313 9346849 1 7361085 3070 2025-06-30 2024-07-01 false 2 2 09102198 0.35 0.35 false 09102198 2024-07-01 2025-06-30 09102198 2 2024-07-01 2025-06-30 09102198 6 2024-07-01 2025-06-30 09102198 2023-07-01 2024-06-30 09102198 2 2023-07-01 2024-06-30 09102198 6 2023-07-01 2024-06-30 09102198 2025-06-30 09102198 2024-06-30 09102198 2023-07-01 09102198 d:Director1 2024-07-01 2025-06-30 09102198 d:Director2 2024-07-01 2025-06-30 09102198 d:RegisteredOffice 2024-07-01 2025-06-30 09102198 e:CurrentFinancialInstruments 2025-06-30 09102198 e:CurrentFinancialInstruments 2024-06-30 09102198 e:ShareCapital 2024-07-01 2025-06-30 09102198 e:ShareCapital 2025-06-30 09102198 e:ShareCapital 2023-07-01 2024-06-30 09102198 e:ShareCapital 2024-06-30 09102198 e:ShareCapital 2023-07-01 09102198 e:RetainedEarningsAccumulatedLosses 2024-07-01 2025-06-30 09102198 e:RetainedEarningsAccumulatedLosses 2025-06-30 09102198 e:RetainedEarningsAccumulatedLosses 2023-07-01 2024-06-30 09102198 e:RetainedEarningsAccumulatedLosses 2024-06-30 09102198 d:OrdinaryShareClass1 2024-07-01 2025-06-30 09102198 d:OrdinaryShareClass1 2025-06-30 09102198 d:OrdinaryShareClass1 2024-06-30 09102198 d:FullIFRS 2024-07-01 2025-06-30 09102198 d:AuditExempt-NoAccountantsReport 2024-07-01 2025-06-30 09102198 d:FullAccounts 2024-07-01 2025-06-30 09102198 d:PrivateLimitedCompanyLtd 2024-07-01 2025-06-30 09102198 e:ContinuingOperations 2024-07-01 2025-06-30 09102198 e:ContinuingOperations 2023-07-01 2024-06-30 09102198 e:ValueBeforeAllowanceForImpairmentLoss 2025-06-30 09102198 e:ValueBeforeAllowanceForImpairmentLoss 2024-06-30 09102198 f:PoundSterling 2024-07-01 2025-06-30 09102198 e:PriorPeriodErrorIncreaseDecrease 2023-07-01 09102198 e:RetainedEarningsAccumulatedLosses e:PriorPeriodErrorIncreaseDecrease 2023-07-01 09102198 e:ShareCapital e:PriorPeriodErrorIncreaseDecrease 2023-07-01 09102198 e:PreviouslyStatedAmount 2023-07-01 09102198 e:RetainedEarningsAccumulatedLosses e:PreviouslyStatedAmount 2023-07-01 iso4217:GBP xbrli:pure xbrli:shares

Registered number: 09102198 LIFECELL COSMETICS LTD UNAUDITED FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
LIFECELL COSMETICS LTD COMPANY INFORMATION
Directors | C V Suarez
| J Pace
Registered number | 09102198
Registered office | 14th Floor
| 33 Cavendish Square
| London
| W1G 0PW
LIFECELL COSMETICS LTD CONTENTS
| Page
Strategic report | 1
Directors' report | 2 - 3
Statement of profit or loss and other comprehensive income | 4
Statement of financial position | 5 - 6
Statement of changes in equity | 7 - 8
Statement of cash flows | 9
Notes to the financial statements | 10 - 17
Detailed profit and loss account and summaries | 17
LIFECELL COSMETICS LTD STRATEGIC REPORT FOR THE YEAR ENDED 30 JUNE 2025
Introduction
The directors present their strategic report for the year ended 30 June 2025.
Principal activities
The principal activity of the company continues to be that of selling cosmetic products.
Principal risks and uncertainties
Although the corona virus pandemic is behind us, there are still inherent risks and uncertainties in conducting international business fuelled by foreign exchange rates and geopolitical events. LifeCell is constantly strategising to stay ahead of these risks and is confident we have suitable plans in action to combat against these risks.
Key performance indicators
The key performance indicators of the company is gross profit. Gross profit during the year was $1,215,619 (2024: $1,829,814). This report was approved by the board on 21 July 2026 and signed on its behalf.
C V Suarez Director
Page 1
LIFECELL COSMETICS LTD DIRECTORS' REPORT FOR THE YEAR ENDED 30 JUNE 2025 The directors present their report and the financial statements for the year ended 30 June 2025.
Directors' responsibilities statement
The directors are responsible for preparing the Strategic report, Directors' report and the financial statements, in accordance with applicable law. Company law requires the directors to prepare financial statements for each financial year. Under that law they have elected to prepare the financial statements in accordance with International Financial Reporting Standards (IFRS) as adopted by the UK. Under company law the directors must not approve the financial statements unless they are satisfied that they give a true and fair view of the state of affairs of the Company and of the profit or loss of the Company for that period. In preparing the financial statements, the directors are required to: ∙select suitable accounting policies and then apply them consistently; ∙make judgements and estimates that are reasonable and prudent; ∙state whether they have been prepared in accordance with IFRS as adopted by the UK, subject to any material departures disclosed and explained in the financial statements; ∙assess the Company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern; and ∙use the going concern basis of accounting unless they either intend to liquidate the Company or to cease operations, or have no realistic alternative but to do so. The directors are responsible for keeping adequate accounting records that are sufficient to show and explain the Company's transactions and disclose with reasonable accuracy at any time the financial position of the Company and enable them to ensure that the financial statements comply with the Companies Act 2006. They are responsible for such internal control as they determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error, and have general responsibility for taking such steps as are reasonably open to them to safeguard the assets of the Company and to prevent and detect fraud and other irregularities.
Results and dividends
The profit for the year, after taxation, amounted to $744,997 (2024 - $461,791).
Directors
The directors who served during the year were:
C V Suarez
J Pace
Page 2
LIFECELL COSMETICS LTD DIRECTORS' REPORT (CONTINUED) FOR THE YEAR ENDED 30 JUNE 2025
Future developments
There has been no significant impact to the running of the company post year end. This report was approved by the board and signed on its behalf.
C V Suarez Director
Date: 21 July 2026
Page 3
LIFECELL COSMETICS LTD STATEMENT OF PROFIT OR LOSS AND OTHER COMPREHENSIVE INCOME FOR THE YEAR ENDED 30 JUNE 2025
|  |  |  | 2025 | 2024
|  |  | Note | $ | $
Revenue |  | 1,611,346 | 2,702,562
Cost of sales |  | (395,727) | (872,748)
Gross profit |  | 1,215,619 | 1,829,814
Administrative expenses |  | 84,244 | (432,063)
Other expenses |  | (212,920) | (595,094)
Profit from operations |  | 1,086,943 | 802,657
Finance income |  | 59,055 | 63,481
Profit before tax |  | 1,145,998 | 866,138
Tax expense | 5 | (401,002) | (404,347)
Total comprehensive income |  | 744,996 | 461,791
The notes on pages 10 to 17 form part of these financial statements.
Page 4
LIFECELL COSMETICS LTD REGISTERED NUMBER: 09102198 STATEMENT OF FINANCIAL POSITION AS AT 30 JUNE 2025
| 2025 | 2024
Note | $ | $
Assets |  |
Non-current assets |  |  |
Current assets |  |  |
Trade and other receivables | 6 | 6,349,185 | 9,994,908
Cash and cash equivalents | 11 | 6,491,862 | 5,282,853
|  | 12,841,047 | 15,277,761
Total assets |  | 12,841,047 | 15,277,761
Liabilities |  |
Non-current liabilities |  |  |
Deferred tax liability | 5 | 247,275 | 70,509
|  | 247,275 | 70,509
Current liabilities |  |  |
Bank overdraft | 11 | - | 9,084
Trade and other liabilities | 7 | 9,395,080 | 12,744,473
|  | 9,395,080 | 12,753,557
Total liabilities |  | 9,642,355 | 12,824,066
Net assets |  | 3,198,692 | 2,453,695
Issued capital and reserves |  |  |
Share capital | 8 | 1,535 | 1,535
Retained earnings |  | 3,197,157 | 2,452,160
TOTAL EQUITY |  | 3,198,692 | 2,453,695
Page 5
LIFECELL COSMETICS LTD REGISTERED NUMBER: 09102198 STATEMENT OF FINANCIAL POSITION (CONTINUED) AS AT 30 JUNE 2025 For the year ending 30 June 2025 the Company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006. The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements. The Company's financial statements have been prepared in accordance with the provisions applicable to the companies subject to the small companies regime. The financial statements on pages 4 to 17 were approved and authorised for issue by the board of directors on 21 July 2026 and were signed on its behalf by:
C V Suarez
Director
The notes on pages 10 to 17 form part of these financial statements. Page 6
LIFECELL COSMETICS LTD STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2025
| Share capital | Retained earnings | Total equity
| $ | $ | $
At 1 July 2024 | 1,535 | 2,452,160 | 2,453,695
Profit for the year | - | 744,996 | 744,996
| - | - | -
Total comprehensive income for the year | - | 744,996 | 744,996
At 30 June 2025 | 1,535 | 3,197,156 | 3,198,691
The notes on pages 10 to 17 form part of these financial statements.
Page 7
LIFECELL COSMETICS LTD STATEMENT OF CHANGES IN EQUITY FOR THE YEAR ENDED 30 JUNE 2024
| Share capital | Retained earnings (restated) | Total equity (restated)
| $ | $ | $
At 1 July 2023 (as previously stated) | 1,535 | 473,211 | 474,746
Prior year adjustment - correction of error | - | 1,517,158 | 1,517,158
At 1 July 2023 (as restated) | 1,535 | 1,990,369 | 1,991,904
Profit for the year | - | 461,791 | 461,791
Total comprehensive income for the year | - | 461,791 | 461,791
At 30 June 2024 | 1,535 | 2,452,160 | 2,453,695
The notes on pages 10 to 17 form part of these financial statements.
Page 8
LIFECELL COSMETICS LTD STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 30 JUNE 2025
|  |  |  | 2025 | 2024
|  |  | Note | $ | $
Cash flows from operating activities |  |  |
Profit for the year |  | 744,996 | 461,791
Adjustments for |  |  |
|  | 744,996 | 461,791
Movements in working capital: |  |  |
Decrease/(increase) in trade and other receivables |  | 3,645,723 | (5,980,256)
(Decrease)/increase in trade and other payables |  | (3,349,392) | 6,888,446
Decrease in provisions |  | 176,766 | 70,509
Cash generated from operations |  | 1,218,093 | 1,440,490
Net increase in cash and cash equivalents |  | 1,218,093 | 1,440,490
Cash and cash equivalents at the beginning of year |  | 5,273,769 | 3,833,279
Cash and cash equivalents at the end of the year | 11 | 6,491,862 | 5,273,769
The notes on pages 10 to 17 form part of these financial statements. Page 9
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 1.Accounting policies
| 1.1 | General information
Lifecell Cosmetics Ltd is a private limited company incorporated in the United Kingdom. The company's registered office is 14th Floor, 33 Cavendish Square, London W1G 0PW. The principal activity of the company is that of a selling cosmetics products.
| 1.2 | Basis of accounting
The Company's financial statements are prepared on a going concern basis and in accordance with International Financial Reporting Standards issued by the International Accounting Standards Board (''IASB'') and interpretations issued by the International Financial Reporting Interpretations Committee of IASB (together ''IFRS'') as adopted by the United Kingdom. The directors deem it be more appropriate to produce the financial statements in accordance with IFRS. The Company's financial statements are prepared in US Dollars and all values are rounded to the nearest Dollar, except, where otherwise indicated. The Company's functional currency is also deemed to be US Dollars.
| 1.3 | Cash and cash equivalents
Cash and cash equivalents comprise cash on hand and demand deposits. For the purpose of the Statement of Cash Flows, cash and cash equivalents consist of cash and cash equivalents as defined above, net of any outstanding bank overdrafts.
| 1.4 | Revenue
Revenue is measured based on the consideration specified in a contract with a customer and excludes amounts collected on behalf of third parties. The Company recognises revenue when it transfers control over a product or service to a customer. The Company does not expect to have any contracts where the period between the transfer of the promised goods or services to the customer and payment by the customer exceeds one year. As a consequence, the Company does not adjust any of the transaction prices for the time value of money. Page 10
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 1.Accounting policies (continued)
| 1.5 | Leasing
Leases are classified as finance leases whenever the terms of the lease transfer substantially all the risks and rewards of ownership to the lessee. All other leases are classified as operating leases.
| The Company as a lessee
The Company assesses whether a contract is or contains a lease, at inception of a contract. The Company recognises a right-of-use asset and a corresponding lease liability with respect to all lease agreements in which it is the lessee, except for short-term leases (defined as leases with a lease term of 12 months or less) and leases of low-value assets. For these leases, the Company recognises the lease payments as an operating expense on a straight-line basis over the term of the lease unless another systematic basis is more representative of the time pattern in which economic benefits from the leased asset are consumed. All of the leases the company has entered into fall into short term and low value so no adjustments have been made in respect of the above. the lease term has changed or there is a change in the assessment of exercise of a purchase option, in which case the lease liability is remeasured by discounting the revised discount rate. Variable rents that do not depend on an index or rate are not included in the measurement of the lease liability and the right-of-use asset. The related payments are recognised as an expense in the period in which the event or condition that triggers those payments occurs and are included in the 'other expenses' line item in profit or loss.
| 1.6 | Financial assets
All regular way purchases or sales of financial assets are recognised and derecognised on a trade date basis. Regular way purchases or sales are purchases or sales of financial assets that require delivery of assets within the time frame established by regulation or convention in the marketplace. All recognised financial assets are subsequently measured in their entirety at either amortised cost or fair value, depending on the classification of the financial assets.
| 1.7 | Financial instruments
Financial assets and financial liabilities are recognised when an entity becomes a party to the contractual provisions of the instruments. Financial assets and financial liabilities are initially measured at fair value. Transaction costs that are directly attributable to the acquisition or issue of financial assets and financial liabilities (other than financial assets and financial liabilities at fair value through profit or loss) are added to or deducted from the fair value of the financial assets or financial liabilities, as appropriate, on initial recognition. Transaction costs directly attributable to the acquisition of financial assets or financial liabilities at fair value through profit or loss are recognised immediately in profit or loss. Page 11
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025 1.Accounting policies (continued)
| 1.8 | Financial liabilities and equity instruments
Financial liabilities and equity instruments are classified according to the substance of the contractual arrangements entered into. An equity instrument is any contract that evidences a residual interest in the assets of the Company after deducting all of its liabilities.
| 1.9 | Functional and presentation currency
These financial statements are presented in US dollars, which is the Company's functional currency.
| 1.10 | Currency translation
Transactions in a currency other than US Dollars (the functional and presentational currency of the Company) are translated into US Dollars at the exchange rate ruling at the date of the transaction. Monetary assets and liabilities denominated in currencies other than US Dollars are, at the reporting date, retranslated at the spot exchange rate on that day. Exchange differences are recognised in profit or loss for the period.
2. | Sigificant accounting judgements, estimates and assumptions
The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the reported amounts of revenues, expenses, assets and liabilities, and the accompanying disclosures, and the disclosure of contingent liabilities. Uncertainty about these assumptions and estimates could result in outcomes that require a material adjustment to the carrying amount of assets or liabilities affected in future periods
3. | Employee
| Employee benefit expenses (including directors) comprise: |  |
| Wages and salaries | 44,935 | 27,661
| The monthly average number of persons, including the directors, employed by the Company during the year was as follows:
|  |  |  |  | 2025 | 2024
|  |  |  |  | No. | No.
| Directors | 2 | 2
Page 12
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
4. | Finance income and expense
| Recognised in profit or loss
|  |  |  |  | 2025 | 2024
|  |  |  |  | $ | $
| Interest on: |  |
| - Bank deposits | 59,055 | 63,481
| Total interest income | 59,055 | 63,481
| Total finance income | 59,055 | 63,481
Page 13
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
5. | Tax expense
| 5.1 Income tax recognised in profit or loss
|  |  |  |  | 2025 | 2024
|  |  |  |  | $ | $
| Current tax |  |
| Overseas tax | 224,236 | 333,838
| Total current tax | 224,236 | 333,838
| Deferred tax expense |  |
| Origination and reversal of timing differences | 176,766 | 70,509
| Total deferred tax | 176,766 | 70,509
|  | 401,002 | 404,347
| The company does not pay UK taxes. The tax charge relates to overseas tax.
|  |  |  |  | 2025 | 2024
|  |  |  |  | $ | $
| Profit for the year | 744,997 | 461,791
| Income tax expense | 401,002 | 404,347
| Profit before income taxes | 1,145,999 | 866,138
| Tax using the Company's domestic tax rate of 35% (2024:35%) | 401,100 | 303,148
| Adjustment for overseas tax | (98) | 101,199
| Total tax expense | 401,002 | 404,347
Page 14
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
6. | Trade and other receivables
|  | 2025 | 2024
|  | $ | $
| Trade receivables | - | 16,826
| Trade receivables - net | - | 16,826
| Prepayments and accrued income | 3,299,660 | 7,051,663
| Other receivables | 3,049,525 | 2,926,419
| Total trade and other receivables | 6,349,185 | 9,994,908
| The directors consider that the carrying amount of trade and other receivables approximates to their fair value. The Company's maximum exposure to credit risk equates to the carrying value of cash and cash equivalents and trade and other receivables.
7. | Trade and other payables
|  | 2025 | 2024
|  | $ | $
| Trade payables | 8,009,048 | 11,347,337
| Payables to related parties | 410,969 | 472,177
| Accruals | 422,448 | 396,387
| Total financial liabilities, excluding loans and borrowings, classified as financial liabilities measured at amortised cost | 8,842,465 | 12,215,901
| Other payables - tax and social security payments | 552,617 | 528,572
| Total trade and other payables | 9,395,082 | 12,744,473
Page 15
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
8. | Share capital
| Authorised |
|  | 2025 | 2025 | 2024 | 2024
|  | Number | $ | Number | $
| Shares treated as equity |  |  |  |
| Ordinary shares of $1.57 each | 978 | 1,535 | 978 | 1,535
|  | 978 | 1,535 | 978 | 1,535
| Issued and fully paid |
|  | 2025 | 2025 | 2024 | 2024
|  | Number | $ | Number | $
| Ordinary shares of $1.57 each |  |  |  |
| At 1 July and 30 June | 978 | 1,535 | 978 | 1,535
9. | Related party transactions
As at the year end, included in other debtors, is a balance of $3,045,887 (2024: $2,921,772) owed to the company by the beneficial owner. As at the year end, a balance of $410,969 (2024: $472,177) was owed to the immediate parent company. During the year the company paid a related party for purchases and marketing fees at an amount of $205,507 (2024: $811,813). As at the year end, included in debtors, is a balance of $3,287,264 (2024: $7,039,116) receivable from an entity with a common director. As at the year end, included in creditors, is a balance of $8,331,337 (2024: $11,743,724) payable to an entity with a common director.
10. | Contolling party
During the year the ultimate controlling party was The CS Family Trust by virtue of their shareholding in the company. Page 16
LIFECELL COSMETICS LTD NOTES TO THE FINANCIAL STATEMENTS FOR THE YEAR ENDED 30 JUNE 2025
11. | Notes supporting statement of cash flows
|  |  |  |  | 2025 | 2024
|  |  |  |  | $ | $
| Cash at bank available on demand | 5,320,272 | 2,738,401
| Short-term deposits | 1,171,590 | 2,544,089
| Cash on hand | - | 363
| Cash and cash equivalents in the statement of financial position | 6,491,862 | 5,282,853
| Bank overdrafts used for cash management purposes | - | (9,084)
| Cash and cash equivalents in the statement of cash flows | 6,491,862 | 5,273,769
Page 17